Vera Therapeutics, Inc. - VERA STOCK NEWS

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET. The company is focused on developing transformative treatments for serious immunological diseases. Investors can participate via a toll-free number or an international line, and a webcast will be available 15 minutes prior to the call. Vera's lead candidate, atacicept, targets autoimmune diseases such as IgA nephropathy and lupus nephritis. For details, visit www.veratx.com.

Vera Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Marshall Fordyce, MD, will present at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The presentation is scheduled for March 9 from 2:10-3:10 PM ET in a corporate panel discussion format. A live audio webcast will be available for those interested. Vera Therapeutics focuses on developing treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting autoimmune diseases like IgA nephropathy and lupus nephritis.

Vera Therapeutics has successfully closed a public offering of 5,742,026 shares of Class A common stock at $15.00 per share, raising approximately $86.1 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 748,959 shares. The offering was managed by J.P. Morgan, Cowen, and Evercore ISI. Registration statements for the securities became effective on February 9 and 10, 2022, and all shares offered were sold by Vera.

Vera Therapeutics, Inc. (Nasdaq: VERA) announced a public offering of 4,993,067 shares of Class A common stock priced at $15.00 per share, aiming to raise approximately $74.9 million before expenses. All shares are offered by the company, with an additional option for underwriters to purchase 748,959 shares within 30 days. The offering is set to close on February 14, 2022, pending customary conditions. J.P. Morgan, Cowen, and Evercore ISI are acting as the joint book-running managers. The securities registration was approved by the SEC on February 9 and 10, 2022.

On February 7, 2022, Vera Therapeutics announced a public offering of 4,000,000 shares of its Class A common stock, with all shares being offered by the company. The underwriters may purchase an additional 600,000 shares within a 30-day option. The offering is subject to market conditions and customary closing prerequisites. J.P. Morgan, Cowen, and Evercore ISI are managing the offering. The registration statement is filed with the SEC and is accessible online. Vera Therapeutics focuses on treatments for serious immunological diseases with candidates like atacicept and MAU868.

Vera Therapeutics announced plans to initiate a Phase 3 trial for atacicept in treating lupus nephritis (LN) following positive feedback from the FDA. The trial will assess the efficacy and safety of atacicept in patients with LN, addressing a critical need as current treatments have limited effectiveness. The trial features a 52-week treatment period, focusing on complete renal response as the primary endpoint. Vera is also advancing trials for other indications, including immunoglobulin A nephropathy (IgAN) and BK virus infections in kidney transplant patients.

Vera Therapeutics, a clinical-stage biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, from 3:45-4:25 PM ET. CEO Marshall Fordyce will lead the presentation and engage in one-on-one investor meetings during the event, taking place virtually from January 10-13, 2022. A live audio webcast of the presentation will be available online, with a replay accessible for 30 days. The company focuses on innovative treatments for serious immunological diseases, including its lead product candidate, atacicept, targeting autoimmune disorders.

Vera Therapeutics has announced the acquisition of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) infections, which is a significant cause of kidney transplant failure. The transaction involves an upfront payment of $5 million and potential milestone payments totaling $7 million. Vera has also secured a $50 million credit facility with Oxford Finance to support further development. MAU868 is currently in a Phase 2 clinical trial, with results expected in mid-2022. This acquisition aligns with Vera’s strategy to enhance its pipeline for immunological diseases.

Vera Therapeutics announces the appointment of Kimball Hall to its board of directors. Hall, with over 30 years of experience in the pharmaceutical industry, is recognized for her leadership roles at Genentech and Amgen, and her current position as president of Abzena, a contract development and manufacturing organization. Her expertise in drug manufacturing and strategic development is expected to enhance Vera's objectives, particularly in advancing its lead clinical candidate, atacicept, aimed at treating serious immunological diseases.